ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
125.15
-2.85 (-2.23%)
Jul 28, 2026, 11:46 AM EDT - Market open
Company Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease.
The company was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme
| Country | France |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 80 |
| CEO | Marc M. de Garidel |
Contact Details
Address: 7-11 Boulevard Haussmann Paris, 75009 France | |
| Phone | 33 1 53 83 09 63 |
| Website | abivax.com |
Stock Details
| Ticker Symbol | ABVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $11.60 |
| CIK Code | 1956827 |
| CUSIP Number | 00370M103 |
| ISIN Number | US00370M1036 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marc M. P. de Garidel M.B.A. | Chief Executive Officer and Director |
| Didier Blondel | EVice President, Chief Financial Officer and Board Secretary |
| Patrick Malloy | Senior Vice President and Head of Investor Relations |
| Ida Hatoum | Chief People and Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 6, 2026 | SCHEDULE 13D/A | Filing |
| Jul 2, 2026 | 6-K | Report of foreign issuer |
| Jul 2, 2026 | 424B5 | Filing |
| Jul 1, 2026 | FWP | Free Writing Prospectus |
| Jun 30, 2026 | FWP | Free Writing Prospectus |
| Jun 30, 2026 | 424B5 | Filing |
| Jun 30, 2026 | POSASR | Filing |
| Jun 29, 2026 | 6-K | Report of foreign issuer |
| Jun 2, 2026 | 6-K | Report of foreign issuer |
| May 22, 2026 | 6-K | Report of foreign issuer |